Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.

Abstract

Introduction: The use of dipeptidyl peptidase-4 inhibitors in hospitalized patients is an area of active research. We aimed to compare the efficacy and the safety of the basal-bolus insulin regimen versus linagliptin-basal insulin in non-critically ill non-cardiac surgery patients in a real-world setting. Methods: We enrolled patients with type 2 diabetes hospitalized in non-cardiac surgery departments with admission glycated haemoglobin level 200 mg/dL (p = .199), and treatment failures (p = .395). Total daily insulin and number of daily insulin injections were lower in the linagliptin-basal group (both p p < .001). Patients on linagliptin-basal insulin had fewer hypoglycaemicevents (blood glucose < 70 mg/dL) (p < .001).Conclusion: For type 2 diabetes surgery patients with mild to moderate hyperglycaemia with-out pre-hospitalization injectable therapies, linagliptin-basal insulin was an effective, safe alterna-tive with fewer hypoglycaemic events in real-world practice.